Skip to main content
Figure 2 | Proteome Science

Figure 2

From: Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

Figure 2

Comparison serum profiles short PFS vs. long PFS. A, six peaks are differential between the two groups: short PFS (red) and long PFS (blue). Six randomly selected peaks. Each overlay contains spectra with normalized intensities. B, Kaplan-Meier (1) time to progression and (2) overall survival curve in NSCLC patients, by prediction of short or long PFS using the 6-peptide signature (intent-to-treat population, n = 27). C, median of the seven differential peaks comparing short PFS (red) and long PFS (blue) over the three time points: pre-treatment (PreTx), after two cycles of treatment (Post-2), and at end of treatment (EOT) (Y-axis: intensity).D, Kaplan-Meier (1) time to progression and (2) overall survival curve in NSCLC patients, by prediction of short or long PFS using the 13-peptide signature (intent-to-treat population, n = 27).

Back to article page

Proteome Science

ISSN: 1477-5956